April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
C20-D3-Vitamin A (ALK-001) rescues the phenotype of an Abca4−/− mouse model of Stargardt disease
Author Affiliations & Notes
  • Peter Charbel Issa
    Nuffield Laboratory of Ophthalmlolgy, University of Oxford, Oxford, United Kingdom
    Department of Ophthalmology, University of Bonn, Bonn, Germany
  • Alun R Barnard
    Nuffield Laboratory of Ophthalmlolgy, University of Oxford, Oxford, United Kingdom
  • Ilyas Washington
    Department of Ophthalmology, Columbia University Medical Center, New York, NY
  • Robert E MacLaren
    Nuffield Laboratory of Ophthalmlolgy, University of Oxford, Oxford, United Kingdom
  • Footnotes
    Commercial Relationships Peter Charbel Issa, None; Alun Barnard, None; Ilyas Washington, Alkeus Pharmaceuticals (C), Alkeus Pharmaceuticals (P); Robert MacLaren, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5015. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Peter Charbel Issa, Alun R Barnard, Ilyas Washington, Robert E MacLaren; C20-D3-Vitamin A (ALK-001) rescues the phenotype of an Abca4−/− mouse model of Stargardt disease. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5015.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To investigate the effect of C20-D3-Vitamin A (ALK-001) on the phenotype of the Abca4−/− mouse

Methods: Abca4−/− mice treated with ALK-001 for various amounts of time (3, 6, 7.5 and 9 months) were compared to untreated Abca4−/− mice and wild type (WT) controls reared on chow containing normal amounts of vitamin A. Quantitative fundus autofluorescence (AF) imaging and electroretinography (ERG) were assessed in vivo (n=10 per group) and assessment of bisretinoid (A2E) accumulation was then performed postmortem

Results: In all Abca4−/− mice that received ALK-001, lipofuscin-related fundus AF levels were significantly lower than in untreated Abca4−/− controls, in which AF levels were about twice those of WT controls at 9 months.The longer animals had stayed on ALK-001, the lower their AF signals. The most significant effect was observed in Abca4−/− mice maintained on ALK-001 for 9 months, with AF signals similar to those of untreated WT controls. When animals were crossed over from ALK-001 to normal chow, AF signals increased steeply. Absence of diet-related changes on scotopic and photopic ERG recordings between the same groups of 9 month-old animals indicated that ALK-001 was safe to the retina. Post-mortem analyses of eye cups revealed an about 8-fold increase of A2E in 9-month old Abca4−/− mice compared to WT controls, while treatment with ALK-001 from birth reduced bisretinoid concentration in eyes of Abca4−/− mice down to the levels measured in WT controls.

Conclusions: These experiments confirm that an increase in the concentration of ocular A2E levels is paralleled by an increase in fundus AF intensity, and that treatment effects of C20-D3-vitamin A (ALK-001) in mice can be monitored with measurement of A2E and AF intensity. Finally, the results demonstrate that ALK-001 can be administered safely in mice and rescues the phenotype of a mouse model of Stargardt disease by reducing the rate of formation of autofluorescent materials in the eyes, without negatively affecting the ERG recordings.

Keywords: 696 retinal degenerations: hereditary • 551 imaging/image analysis: non-clinical  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×